STAT+: Large Drugmakers Are Developing Fewer Antibiotics, Analysis Finds

Why It Matters

The contraction of antibiotic pipelines threatens to widen the gap between rising antimicrobial resistance and available treatments, especially for children in low‑income regions, undermining public‑health security.

Key Takeaways

• Antimicrobial projects fell 35% to 60 in five years
• Only 13% of pipelines target children under five
• No pediatric formulations registered in 17 sub‑Saharan African nations
• Companies still register other drugs in ten of those countries
• Decline raises risk of unchecked superbug resistance worldwide

Pulse Analysis

The decline in large‑pharma antibiotic pipelines reflects a broader market reality: developing new antimicrobials is costly, yields modest returns, and faces stringent regulatory scrutiny. Over the last half‑decade, major firms have redirected resources toward chronic‑disease therapeutics and biologics, where profit margins are higher. This shift leaves a shrinking pool of novel agents to combat evolving bacterial resistance, prompting public‑health officials to warn of a looming treatment vacuum if private investment does not rebound.

Pediatric antibiotic development lags even further behind. Of the 39 projects targeting WHO‑identified priority pathogens, only five address children under five, and each must first secure adult approval before pursuing pediatric trials—a process that can add years and substantial expense. The scarcity of child‑specific formulations hampers clinicians’ ability to treat severe infections in the most vulnerable age group, potentially increasing mortality and fostering resistant strains that spread beyond pediatric settings. Strengthening incentives such as extended market exclusivity and streamlined pediatric study pathways could help bridge this gap.

Geographic inequities compound the problem, with 17 sub‑Saharan African nations lacking any registered pediatric antimicrobial products from the assessed companies. While some firms have introduced other medicines in ten of these markets, the absence of child‑focused antibiotics underscores systemic barriers, including limited regulatory capacity and uncertain commercial returns. Addressing these disparities will require coordinated policy action—global funding mechanisms, tiered pricing models, and partnerships with local health authorities—to ensure that life‑saving antibiotics reach children wherever the superbug threat emerges.